[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369622-105":59,"doc-detail-369622-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","global-regional-and-national-burden-and-trends-of-soft-tissue-and-other-extraosseous-sarcomas-from-1990-to-2021-cancer-control-volume-32","Global, Regional, and National Burden and Trends of Soft Tissue and Other Extraosseous Sarcomas From 1990 to 2021 - Cancer Control Volume 32","","Soft Tissue and Other Extraosseous Sarcomas (STOES) are rare, heterogeneous cancers with major clinical challenges. A comprehensive analysis used Global Health Data Exchange (GHDx) data from 1990–2021 to estimate incidence, prevalence, mortality, and Disability-Adjusted Life Years (DALYs) by location, sex, and socio-demographic indices. In 2021, global prevalence reached 480,473, with the highest age-standardized incidence and prevalence in high SDI regions, and notable increases in Central Asia and Central Europe. Population growth and aging drove trends; a decline is forecast by 2030, but male and regional disparities are expected to persist.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/global-regional-and-national-burden-and-trends-of-soft-tissue-and-other-extraosseous-sarcomas-from-1990-to-2021-cancer-control-volume-32/369622/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/global-regional-and-national-burden-and-trends-of-soft-tissue-and-other-extraosseous-sarcomas-from-1990-to-2021-cancer-control-volume-32/369622.png","ImageObject",300,407,{"name":92,"@type":93},"Putri","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What cancers are covered in the study and why are they important?","Question",{"text":113,"@type":114},"The study focuses on Soft Tissue and Other Extraosseous Sarcomas (STOES), a rare and heterogeneous malignancy group. Their complexity and aggressiveness create substantial clinical challenges despite low prevalence.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were trends in STOES measured from 1990 to 2021?",{"text":118,"@type":114},"Researchers analyzed Global Health Data Exchange (GHDx) data for 1990–2021. They estimated incidence, prevalence, mortality, and DALYs, using EAPC, Spearman correlation, and Bayesian age-period-cohort modeling.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key findings for 2021 and what drove the observed trends?",{"text":122,"@type":114},"In 2021, global prevalence was estimated at 480,473, higher than in 1990. High SDI regions had the highest age-standardized rates, with increases also seen in several regions; decomposition indicated population growth and aging as primary drivers.",{"name":124,"@type":111,"acceptedAnswer":125},"Will the global burden decrease by 2030, and what disparities are expected to remain?",{"text":126,"@type":114},"Forecasting suggests a decline in global STOES burden by 2030. However, disparities are expected to persist, particularly among males and across certain geographic regions, supporting the need for targeted public health actions.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},369622,1790218112,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","| Global, Regional, and National Burden and Trends of Soft Tissue and Other Extraosseous Sarcomas From 1990 to 2021 | Cancer Control Volume 32: 1-14 © The Author(s) 2025 Article reuse guidelines:\u003Cbr>[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/10732748251355841](DOI: 10.1177/10732748251355841)\u003Cbr>[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)\u003Cbr>\u003Cbr>|\n| --- | --- |\n| Rui Zhu, MD 1, Ziyuan Shen, PhD2, Haijuan Zhu, MD 1, Jisen Zhang, MD3, Xing Xing, MS4, Shengyou Wang, MD 1, and Jialiu Fang, MD3 􀀁\u003Cbr>Abstract\u003Cbr>Introduction: Soft Tissue and Other Extraosseous Sarcomas (STOES) represent a rare and heterogeneous group of malignancies with signiﬁcant clinical challenges due to their complexity and aggressiveness. Despite their low prevalence, the global impact of STOES is substantial, necessitating a detailed examination of their epidemiology and disease burden. Methods: This comprehensive analysis utilized data from the Global Health Data Exchange (GHDx) covering the years 1990 to 2021. We assessed the incidence, prevalence, mortality, and Disability-Adjusted Life Years (DALYs) for STOES, categorized by location, sex, and socio-demographic indices. Statistical methods included Estimated Annual Percentage Change (EAPC), Spearman correlation analysis, and Bayesian age-period-cohort modeling. Findings: In 2021, STOES cases reached a global prevalence of 480,473, a signiﬁcant increase from 1990. High Socio-Demographic Index (SDI) regions exhibited the highest age-standardized incidence and prevalence rates (ASIR and ASPR) at 2.05 and 10.61 per 100,000 population, respectively. Notably, signiﬁcant increases were also observed in Central Asia, Central Europe, and Southern Sub-Saharan Africa. Males consistently showed higher disease rates than females. The decomposition analysis highlighted population growth and aging as primary drivers of the observed trends. Forecasting suggests a decline in the global STOES burden by 2030, though disparities will persist, particularly among males. Conclusion: The study reveals critical geographic and demographic disparities in the burden of STOES, underscoring the ongoing higher risk among males and in certain global regions. Despite projected declines in overall disease burden by 2030, substantial disparities are expected to persist, necessitating targeted public health interventions and robust policies to effectively mitigate these differences and enhance global health outcomes.\u003Cbr>Plain Language Summary\u003Cbr>Why was the study done? This study was conducted to understand the global impact of rare cancers known as soft tissue and other extraosseous sarcomas (STOES). These cancers, although rare, signiﬁcantly affect patients worldwide, making it important to monitor their occurrence and impact. What did the researchers do? We analyzed global health data from 1990 to 2021 to ﬁnd out how many people are diagnosed with these cancers each year, how many live with them, and how many die from them. We examined these trends across different global regions and among various demographic groups. What did the |  |\n| 1 Department of Anesthesiology, Hefei Maternal and Child Health Hospital, Anhui Maternal and Child Health Care Hospital, Hefei Fifth People’s Hospital, Maternal and Child Health Care Hospital of Anhui Medical University, Hefei, China\u003Cbr>2Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China 3Department of Orthopedics, The Second Afﬁliated Hospital of Anhui Medical University, Hefei, China 4Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA\u003Cbr>Corresponding Authors:\u003Cbr>Shengyou Wang, Department of Anesthesiology, Hefei Maternal and Child Health Hospital, Anhui Maternal and Child Health Care Hospital, Maternal and Child Health Care Hospital of Anhui Medical University, 15 Yimin Street, Hefei 230001, China.\u003Cbr>Email","cbCaiaKpYWQxLl8v","https://ap.wps.com/l/cbCaiaKpYWQxLl8v","pdf",1907823,14,"English","# Abstract\n## Introduction\n## Methods\n## Findings\n## Conclusion\n# Plain Language Summary\n## Why was the study done?\n## What did the researchers do?\n## What did the findings mean?","[{\"question\":\"What cancers are covered in the study and why are they important?\",\"answer\":\"The study focuses on Soft Tissue and Other Extraosseous Sarcomas (STOES), a rare and heterogeneous malignancy group. Their complexity and aggressiveness create substantial clinical challenges despite low prevalence.\"},{\"question\":\"How were trends in STOES measured from 1990 to 2021?\",\"answer\":\"Researchers analyzed Global Health Data Exchange (GHDx) data for 1990–2021. They estimated incidence, prevalence, mortality, and DALYs, using EAPC, Spearman correlation, and Bayesian age-period-cohort modeling.\"},{\"question\":\"What were the key findings for 2021 and what drove the observed trends?\",\"answer\":\"In 2021, global prevalence was estimated at 480,473, higher than in 1990. High SDI regions had the highest age-standardized rates, with increases also seen in several regions; decomposition indicated population growth and aging as primary drivers.\"},{\"question\":\"Will the global burden decrease by 2030, and what disparities are expected to remain?\",\"answer\":\"Forecasting suggests a decline in global STOES burden by 2030. However, disparities are expected to persist, particularly among males and across certain geographic regions, supporting the need for targeted public health actions.\"}]","Global, Regional, and National Burden and Trends of Soft Tissue and Other Extraosseous Sarcomas From 1990 to 2021 - Cancer Control Volume 32 | PDF",1790183720,35,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15d27872fdd3cae7e9dae1669f88ef1a.webp",983,1272,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26b0c9e7f4fe1325e058c780fb21170d.webp",982,1270,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f9262c3f627f67f78c68d21d57cbd44.webp",981,1269,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1112c274f4f67ddd5e35340790ac8be5.webp",980,1268]